World Cancer Day: United by Unique – Inspiring Stories from People Affected by Cancer Every year, February 4th marks World Cancer Day, an initiative led by the Union for Read More » AI Over Two Decades of AI-Powered Precision: How Synchrony has Revolutionized Real-time Adaptive Radiotherapy...
Mancosu P, Clemente S, Landoni V, Ruggieri R, Alongi F, Scorsetti M, et al. SBRT for prostate cancer: challenges and features from a physicist prospective. Phys Med 2016;32(3):479-84.Mancosu P, Clemente S, Landoni V, et al. SBRT for prostate cancer:challenges and features from a ...
参考文献: [1]PACE-A:An international phase 3 randomised controlled trial(RCT)comparing stereotactic body radiotherapy(SBRT)to surgery for localised prostate cancer(LPCa)—Primary endpoint analysis.ASCO-GU 203;Abstract:298 [2]10-Year efficacy and co-morbidity outcomes of a phase III randomised trial...
SBRT for clinically localized prostate cancer was well tolerated, with an early biochemical response similar to other radiation therapy treatments. Benign PSA bounces were common. Late GI and GU toxicity rates were comparable to conventionally fractionated radiation therapy and brachytherapy. Late urinary ...
Radiotherapy is an increasingly preferred treatment option for localized prostate cancer, and stereotactic body radiation therapy (SBRT) a relatively established modality of therapeutic irradiation. The present study analyzes the toxicity and biochemical efficacy of SBRT in 100 consecutive prostate cancer ...
Aims: to optimise linear accelerator-based prostate stereotactic ablative radiotherapy (SABR) through planning studies, tumour control probability (TCP) and normal tissue complication probability (NTCP) calculations and radiation-induced second primary cancer (RISPC) risk assessment. Methods: A planning stu...
[2]10-Year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional vs.hypofractionated high dose intensity modulated radiotherapy for prostate cancer(CHHiP;CRUK/06/016).ASCO-GU 203;Abstract:304 [3]Dearnaley D,Syndikus I,Mossop H,et al.Conventional versus hypofractionate...
SBRT may as well potentially prolong the time before the initiation of androgen deprivation therapy (ADT) and docetaxel chemotherapy for oligometastatic prostate cancer. The goal of this study is to outline prognostic factors associated with improved outcome with SBRT for metastatic prostate cancer and ...
These data add to the growing body of literature on SBRT for prostate cancer and provide crucial insights into the long-term outcomes of this therapy. “SBRT trials continue to accrue and to extend follow-up,” says King. He adds that further trials with greater numbers of participants and ...
Prostate cancer (PC) is currently the most common male cancer in most western countries, representing 30% of malignant tumors in men (Jemal et al. 2006). The major prognostic factors in localized prostate cancer are Gleason score, initial prostate-specific antigen (iPSA) and T stage. The ...